Throughout the last three months, 5 analysts have evaluated Bio-Rad Laboratories (NYSE:BIO), offering a diverse set of opinions from bullish to bearish.

The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $378.4, a high estimate of $401.00, and a low estimate of $340.00. This upward trend is evident, with the current average reflecting a 4.17% increase from the previous average price target of $363.25.

Analyzing Analyst Ratings: A Detailed Breakdown

The standing of Bio-Rad Laboratories among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Bio-Rad Laboratories's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on Bio-Rad Laboratories analyst ratings.

Unveiling the Story Behind Bio-Rad Laboratories

Financial Milestones: Bio-Rad Laboratories's Journey

Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.

Revenue Growth: Bio-Rad Laboratories's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -6.26%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Bio-Rad Laboratories's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -339.16%, the company may face hurdles in effective cost management.

Return on Equity (ROE): Bio-Rad Laboratories's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -27.36%, the company may encounter challenges in delivering satisfactory returns for shareholders.

Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -19.42%, the company may need to address challenges in generating satisfactory returns from its assets.

Debt Management: With a below-average debt-to-equity ratio of 0.21, Bio-Rad Laboratories adopts a prudent financial strategy, indicating a balanced approach to debt management.

Analyst Ratings: Simplified

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.